{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T00:11:41Z","timestamp":1793664701084,"version":"4.5.1"},"reference-count":44,"publisher":"BMJ","license":[{"start":{"date-parts":[[2023,4,6]],"date-time":"2023-04-06T00:00:00Z","timestamp":1680739200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ"],"accepted":{"date-parts":[[2023,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To compare the benefits and harms of drug treatments for adults with type 2 diabetes, adding non-steroidal mineralocorticoid receptor antagonists (including finerenone) and tirzepatide (a dual glucose dependent insulinotropic polypeptide (GIP)\/glucagon-like peptide-1 (GLP-1) receptor agonist) to previously existing treatment options.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Systematic review and network meta-analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data sources<\/jats:title>\n                    <jats:p>Ovid Medline, Embase, and Cochrane Central up to 14 October 2022.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Eligibility criteria for selecting studies<\/jats:title>\n                    <jats:p>Eligible randomised controlled trials compared drugs of interest in adults with type 2 diabetes. Eligible trials had a follow-up of 24 weeks or longer. Trials systematically comparing combinations of more than one drug treatment class with no drug, subgroup analyses of randomised controlled trials, and non-English language studies were deemed ineligible. Certainty of evidence was assessed following the GRADE (grading of recommendations, assessment, development and evaluation) approach.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The analysis identified 816 trials with 471 038 patients, together evaluating 13 different drug classes; all subsequent estimates refer to the comparison with standard treatments. Sodium glucose cotransporter-2 (SGLT-2) inhibitors (odds ratio 0.88, 95% confidence interval 0.83 to 0.94; high certainty) and GLP-1 receptor agonists (0.88, 0.82 to 0.93; high certainty) reduce all cause death; non-steroidal mineralocorticoid receptor antagonists, so far tested only with finerenone in patients with chronic kidney disease, probably reduce mortality (0.89, 0.79 to 1.00; moderate certainty); other drugs may not. The study confirmed the benefits of SGLT-2 inhibitors and GLP-1 receptor agonists in reducing cardiovascular death, non-fatal myocardial infarction, admission to hospital for heart failure, and end stage kidney disease. Finerenone probably reduces admissions to hospital for heart failure and end stage kidney disease, and possibly cardiovascular death. Only GLP-1 receptor agonists reduce non-fatal stroke; SGLT-2 inhibitors are superior to other drugs in reducing end stage kidney disease. GLP-1 receptor agonists and probably SGLT-2 inhibitors and tirzepatide improve quality of life. Reported harms were largely specific to drug class (eg, genital infections with SGLT-2 inhibitors, severe gastrointestinal adverse events with tirzepatide and GLP-1 receptor agonists, hyperkalaemia leading to admission to hospital with finerenone). Tirzepatide probably results in the largest reduction in body weight (mean difference \u22128.57 kg; moderate certainty). Basal insulin (mean difference 2.15 kg; moderate certainty) and thiazolidinediones (mean difference 2.81 kg; moderate certainty) probably result in the largest increases in body weight. Absolute benefits of SGLT-2 inhibitors, GLP-1 receptor agonists, and finerenone vary in people with type 2 diabetes, depending on baseline risks for cardiovascular and kidney outcomes (\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/matchit.magicevidence.org\/230125dist-diabetes\">https:\/\/matchit.magicevidence.org\/230125dist-diabetes<\/jats:ext-link>\n                      ).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This network meta-analysis extends knowledge beyond confirming the substantial benefits with the use of SGLT-2 inhibitors and GLP-1 receptor agonists in reducing adverse cardiovascular and kidney outcomes and death by adding information on finerenone and tirzepatide. These findings highlight the need for continuous assessment of scientific progress to introduce cutting edge updates in clinical practice guidelines for people with type 2 diabetes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic review registration<\/jats:title>\n                    <jats:p>PROSPERO CRD42022325948.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmj-2022-074068","type":"journal-article","created":{"date-parts":[[2023,4,6]],"date-time":"2023-04-06T07:10:30Z","timestamp":1680765030000},"page":"e074068","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":259,"title":["Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials"],"prefix":"10.1136","volume":"381","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4299-5889","authenticated-orcid":false,"given":"Qingyang","family":"Shi","sequence":"first","affiliation":[{"name":"Department of Endocrinology and Metabolism, Division of Guideline and Rapid Recommendation, Cochrane China Centre, MAGIC China Centre, Chinese Evidence-Based Medicine Centre, West China Hospital, Sichuan University, Chengdu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kailei","family":"Nong","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Division of Guideline and Rapid Recommendation, Cochrane China Centre, MAGIC China Centre, Chinese Evidence-Based Medicine Centre, West China Hospital, Sichuan University, Chengdu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per Olav","family":"Vandvik","sequence":"additional","affiliation":[{"name":"Department of Medicine, Lovisenberg Diaconal Hospital, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gordon H","family":"Guyatt","sequence":"additional","affiliation":[{"name":"Department of Health Research Methods, Evidence and Impact, McMaster University, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Schnell","sequence":"additional","affiliation":[{"name":"Forschergruppe Diabetes eV at the Helmholtz Centre, Munich-Neuherberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Ryd\u00e9n","sequence":"additional","affiliation":[{"name":"Department of Medicine K2, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaus","family":"Marx","sequence":"additional","affiliation":[{"name":"Clinic for Cardiology, Angiology, and Intensive Care Medicine, RWTH Aachen University, University Hospital Aachen, Aachen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"III","given":"Frank C","family":"Brosius","sequence":"additional","affiliation":[{"name":"Division of Nephrology, University of Arizona College of Medicine Tucson, Tucson, AZ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reem A","family":"Mustafa","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Nephrology and Hypertension, University of Kansas, Kansas City, MI, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnav","family":"Agarwal","sequence":"additional","affiliation":[{"name":"Department of Health Research Methods, Evidence and Impact, McMaster University, ON, Canada"},{"name":"Department of Medicine, McMaster University, Hamilton, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyu","family":"Zou","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Division of Guideline and Rapid Recommendation, Cochrane China Centre, MAGIC China Centre, Chinese Evidence-Based Medicine Centre, West China Hospital, Sichuan University, Chengdu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunhe","family":"Mao","sequence":"additional","affiliation":[{"name":"Department of Orthopedics, Orthopedic Research Institute, West China Hospital, Sichuan University, Chengdu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aminreza","family":"Asadollahifar","sequence":"additional","affiliation":[{"name":"Digestive Disease Research Institute, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saifur Rahman","family":"Chowdhury","sequence":"additional","affiliation":[{"name":"Department of Health Research Methods, Evidence and Impact, McMaster University, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunjuan","family":"Zhai","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Shandong Provincial Hospital affiliated to Shandong First Medical University, Jinan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sana","family":"Gupta","sequence":"additional","affiliation":[{"name":"Department of Health Research Methods, Evidence and Impact, McMaster University, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Health Research Methods, Evidence and Impact, McMaster University, ON, Canada"},{"name":"Evidence-Based Medicine Centre, School of Basic Medical Sciences, Lanzhou University, Lanzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00e3o Pedro","family":"Lima","sequence":"additional","affiliation":[{"name":"Department of Health Research Methods, Evidence and Impact, McMaster University, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Numata","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine, St Marianna University School of Medicine, Kawasaki, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi","family":"Qiao","sequence":"additional","affiliation":[{"name":"West China School of Medicine, Sichuan University, Chengdu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinlin","family":"Fan","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Division of Guideline and Rapid Recommendation, Cochrane China Centre, MAGIC China Centre, Chinese Evidence-Based Medicine Centre, West China Hospital, Sichuan University, Chengdu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinbo","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Nephrology, National Clinical Research Centre for Geriatrics, West China Hospital, Sichuan University, Chengdu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinghui","family":"Jin","sequence":"additional","affiliation":[{"name":"Center for Evidence-Based and Translational Medicine, Zhongnan Hospital of Wuhan University, Wuhan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Long","family":"Ge","sequence":"additional","affiliation":[{"name":"Evidence-Based Social Science Research Centre, School of Public Health, Lanzhou University, Lanzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuyu","family":"Yang","sequence":"additional","affiliation":[{"name":"Evidence-Based Nursing Centre, School of Nursing, Lanzhou University, Lanzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongfei","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Social Medicine and Health Management, School of Public Health, Lanzhou University, Lanzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Chengdu Fifth People\u2019s Hospital, Chengdu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe","family":"Chen","sequence":"additional","affiliation":[{"name":"Evidence-Based Medicine Centre, Tianjin University of Traditional Chinese Medicine, Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Division of Guideline and Rapid Recommendation, Cochrane China Centre, MAGIC China Centre, Chinese Evidence-Based Medicine Centre, West China Hospital, Sichuan University, Chengdu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyu","family":"He","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Surgery, West China Hospital, Sichuan University, Chengdu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangyang","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, First People\u2019s Hospital of Shuangliu District, Chengdu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiafei","family":"Lyu","sequence":"additional","affiliation":[{"name":"Department of Radiology, West China Hospital, Sichuan University, Chengdu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingxing","family":"An","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Division of Guideline and Rapid Recommendation, Cochrane China Centre, MAGIC China Centre, Chinese Evidence-Based Medicine Centre, West China Hospital, Sichuan University, Chengdu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaolong","family":"Chen","sequence":"additional","affiliation":[{"name":"Evidence-Based Social Science Research Centre, School of Public Health, Lanzhou University, Lanzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiukui","family":"Hao","sequence":"additional","affiliation":[{"name":"School of Rehabilitation Science, McMaster University, Hamilton, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eberhard","family":"Standl","sequence":"additional","affiliation":[{"name":"Forschergruppe Diabetes eV at the Helmholtz Centre, Munich-Neuherberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reed","family":"Siemieniuk","sequence":"additional","affiliation":[{"name":"Department of Health Research Methods, Evidence and Impact, McMaster University, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Agoritsas","sequence":"additional","affiliation":[{"name":"Department of Health Research Methods, Evidence and Impact, McMaster University, ON, Canada"},{"name":"Division of General Internal Medicine, Division of Clinical Epidemiology, University Hospitals of Geneva, Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoming","family":"Tian","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Division of Guideline and Rapid Recommendation, Cochrane China Centre, MAGIC China Centre, Chinese Evidence-Based Medicine Centre, West China Hospital, Sichuan University, Chengdu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0060-0287","authenticated-orcid":false,"given":"Sheyu","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Division of Guideline and Rapid Recommendation, Cochrane China Centre, MAGIC China Centre, Chinese Evidence-Based Medicine Centre, West China Hospital, Sichuan University, Chengdu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2023,4,6]]},"reference":[{"key":"2025110102161986000_381.apr06_3.e074068.1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(16)30162-0"},{"key":"2025110102161986000_381.apr06_3.e074068.2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m4573"},{"key":"2025110102161986000_381.apr06_3.e074068.3","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n1091"},{"key":"2025110102161986000_381.apr06_3.e074068.4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2025845"},{"key":"2025110102161986000_381.apr06_3.e074068.5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2110956"},{"key":"2025110102161986000_381.apr06_3.e074068.6","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01324-6"},{"key":"2025110102161986000_381.apr06_3.e074068.7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107519"},{"key":"2025110102161986000_381.apr06_3.e074068.8","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01443-4"},{"key":"2025110102161986000_381.apr06_3.e074068.9","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)02188-7"},{"key":"2025110102161986000_381.apr06_3.e074068.10","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.0078"},{"key":"2025110102161986000_381.apr06_3.e074068.11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMe2210531"},{"key":"2025110102161986000_381.apr06_3.e074068.12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2200433"},{"key":"2025110102161986000_381.apr06_3.e074068.13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2200436"},{"key":"2025110102161986000_381.apr06_3.e074068.14","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2021.108870"},{"key":"2025110102161986000_381.apr06_3.e074068.15","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71"},{"key":"2025110102161986000_381.apr06_3.e074068.16","doi-asserted-by":"publisher","DOI":"10.7326\/M14-2385"},{"key":"2025110102161986000_381.apr06_3.e074068.17","unstructured":"Guyatt G, Busse J. Methods Commentary: Risk of Bias in Randomized Trials 1. DistillerSR. 2011. https:\/\/www.distillersr.com\/resources\/methodological-resources\/risk-of-bias-commentary."},{"key":"2025110102161986000_381.apr06_3.e074068.18","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2020.07.013"},{"key":"2025110102161986000_381.apr06_3.e074068.19","doi-asserted-by":"publisher","DOI":"10.1002\/jrsm.1058"},{"key":"2025110102161986000_381.apr06_3.e074068.20","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01640-8"},{"key":"2025110102161986000_381.apr06_3.e074068.21","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.2012.664484"},{"key":"2025110102161986000_381.apr06_3.e074068.22","doi-asserted-by":"publisher","DOI":"10.1002\/jrsm.1044"},{"key":"2025110102161986000_381.apr06_3.e074068.23","doi-asserted-by":"publisher","DOI":"10.1002\/sim.6001"},{"key":"2025110102161986000_381.apr06_3.e074068.24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2020.03.010"},{"key":"2025110102161986000_381.apr06_3.e074068.25","doi-asserted-by":"publisher","DOI":"10.1002\/sim.8158"},{"key":"2025110102161986000_381.apr06_3.e074068.26","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.200077"},{"key":"2025110102161986000_381.apr06_3.e074068.27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2010.07.015"},{"key":"2025110102161986000_381.apr06_3.e074068.28","doi-asserted-by":"publisher","DOI":"10.1002\/sim.9346"},{"key":"2025110102161986000_381.apr06_3.e074068.29","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.g5630"},{"key":"2025110102161986000_381.apr06_3.e074068.30","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2021.03.026"},{"key":"2025110102161986000_381.apr06_3.e074068.31","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2022.07.014"},{"key":"2025110102161986000_381.apr06_3.e074068.32","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m3900"},{"key":"2025110102161986000_381.apr06_3.e074068.33","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-056400"},{"key":"2025110102161986000_381.apr06_3.e074068.34","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2021-319243"},{"key":"2025110102161986000_381.apr06_3.e074068.35","doi-asserted-by":"publisher","DOI":"10.2337\/dc21-1113"},{"key":"2025110102161986000_381.apr06_3.e074068.36","doi-asserted-by":"publisher","DOI":"10.2337\/dc22-0294"},{"key":"2025110102161986000_381.apr06_3.e074068.37","doi-asserted-by":"publisher","DOI":"10.1253\/circj.CJ-16-0122"},{"key":"2025110102161986000_381.apr06_3.e074068.38","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfac157"},{"key":"2025110102161986000_381.apr06_3.e074068.39","unstructured":"Bayer. A Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Finerenone on Morbidity and Mortality in Participants With Heart Failure (NYHA II-IV) and Left Ventricular Ejection Fraction \u2265 40% (LVEF \u2265 40%). Clinicaltrials.gov. 2022. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04435626."},{"key":"2025110102161986000_381.apr06_3.e074068.40","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2021.105835"},{"key":"2025110102161986000_381.apr06_3.e074068.41","unstructured":"Eli Lilly and Company. The Effect of Tirzepatide Versus Dulaglutide on Major Adverse Cardiovascular Events in Patients With Type 2 Diabetes (SURPASS-CVOT). clinicaltrials.gov 2022. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04255433."},{"key":"2025110102161986000_381.apr06_3.e074068.42","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-020-0399-8"},{"key":"2025110102161986000_381.apr06_3.e074068.43","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14075"},{"key":"2025110102161986000_381.apr06_3.e074068.44","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-021-01276-9"}],"container-title":["BMJ"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/data.bmj.org\/tdm\/10.1136\/bmj-2022-074068","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmj-2022-074068","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T09:16:29Z","timestamp":1761988589000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.bmj.com\/lookup\/doi\/10.1136\/bmj-2022-074068"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,6]]},"references-count":44,"alternative-id":["10.1136\/bmj-2022-074068"],"URL":"https:\/\/doi.org\/10.1136\/bmj-2022-074068","relation":{},"ISSN":["1756-1833"],"issn-type":[{"value":"1756-1833","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,6]]}}}